Pacific Biosciences of California Inc. (NASDAQ:PACB) finished Thursday with a subtraction of -$0.31 to close at $5.41, a downside of -5.42 percent. An average of 6,162,880 shares of common stock have been traded in the last five days. There was a fall of -$1.20 in the past week, and it reached a new high 5 times over the past 12 months. The last 20 days have seen an average of 5,981,030 shares traded, while the 50-day average volume stands at 8,500,614.
PACB stock has decreased by -9.98% in the last month. The company shares reached their 1-month lowest point of $5.07 on 09/02/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $3.85 and a high of $31.10 in 52 weeks. It has reached a new high 2 times so far this year and lost -73.56% or -$15.05 in price. In spite of this, the price is down -82.60% from the 52-week high.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
8 days have passed since Pacific Biosciences of California Inc. (PACB) last reported insider trading activity. HENRY CHRISTIAN O, who is, most recently acquired $91,307 shares at $5.78 per share on Sep 15. In this transaction, the insider spent $527,435., Farmer Michele, disposed of 3,573 shares at a price of $5.55 on May 18. The insider now owns more than $19,819 worth of shares. Prior to that, Chief Financial Officer Kim Susan G. went on to Sale 1,062 shares at $11.06 each on Feb 17. An amount of $11,746 was transacted.
Pacific Biosciences of California Inc. (PACB) stock’s beta is 1.30. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.57, the price-to-book (PB) ratio at 1.78.
The quick ratio of Pacific Biosciences of California Inc. for the three months ended March 30 was 11.10, and the current ratio was 11.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.31 and a total debt to equity ratio of 1.31 for the quarter ending March 30. Its gross profit as reported stood at $58.86 million compared to revenue of $130.51 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Pacific Biosciences of California Inc.’s return on assets was -10.50%.
For the three-month period that ended March 30, Pacific Biosciences of California Inc. had $588.71 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$71.39 million in the quarter, while revenues of -$81.5 million were grew 42.57%. The analyst consensus anticipated Pacific Biosciences of California Inc.’s latest quarter earnings to come in at -$0.31 per share, but it turned out to be -$0.37, a -19.40% surprise. For the quarter, EBITDA amounted to -$63.16 million. Shareholders own equity worth $224.84 million.
From a technical analysis perspective, let’s take a brief look at Pacific Biosciences of California Inc. (PACB) price momentum. RSI 9-day as of the close on 22 September was 38.15%, suggesting the stock is Neutral, with historical volatility in this time frame at 92.26%.
As of today, PACB’s price is $5.81 -18.15% or -$1.20 from its 5-day moving average. PACB is currently trading -17.66% lower than its 20-day SMA and -14.67% lower than its 100-day SMA. However, the stock’s current price level is +5.66% above the SMA50 and -73.20% below the SMA200.
The stochastic %K and %D were 27.95% and 36.71%, respectively, and the average true range (ATR) was 0.65. With the 14-day stochastic at 16.39% and the average true range at 0.70, the RSI (14) stands at 42.92%. The stock has reached -0.45 on the 9-day MACD Oscillator while the 14-day reading was at -0.38.